Results 141 to 150 of about 19,727 (209)

Influence of antiviral treatment in hepatitis C patients on metabolism and fibrosis process. [PDF]

Front Med (Lausanne)
Jędrysik M, Tomasiewicz K, Chełstowska B, Tudrujek-Zdunek M, Szymański FM.   +4 more
europepmc   +1 more source

Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes. [PDF]

Viruses
AlKaabi H, AlSinani S, El-Kassas M, Alswat KA, AlNaamani KM.   +4 more
europepmc   +1 more source

Health Disparities in Achieving Sustained Virologic Response Among Patients With Chronic Hepatitis C: A Retrospective Single-Center Study. [PDF]

Cureus
Leach E, Rana R, Nguyen C, Reinecke J, Hall A, Velagapudi M.   +5 more
europepmc   +1 more source

Efficacy of Sofosbuvir-Velpatasvir-Ribavirin Regimen for Retreatment of Chronic Hepatitis C in Patients With Prior DAA Failure: A Retrospective Study From a National Treatment Center. [PDF]

Int J Hepatol
Singh S, Sengupta S, Kumar D, Mukherjee K, Hasan AMD, Sadhukhan P, Ahammed SM.   +6 more
europepmc   +1 more source

Hepatitis C Virus (HCV) Recurrence and Death After Viral Clearance in an HCV-Viremic Donor to HCV-Negative Kidney Recipient. [PDF]

Kidney Med
He S, Tanaka T, Kim SH, Thomsen D, Katz DA, Thomas CP, Rastogi P, Aziz H, Reed AI.   +8 more
europepmc   +1 more source

To treat or not to treat young children with hepatitis C?--real-life experience. [PDF]

Eur J Pediatr
Pokorska-Śpiewak M, Dobrzeniecka A, Talarek E, Aniszewska M, Marczyńska M.   +4 more
europepmc   +1 more source

Identification of potential inhibitors of the main protease from feline infectious peritonitis virus using molecular docking and dynamic simulation approaches. [PDF]

PeerJ
Khan MY, Shah AU, Duraisamy N, Moawad N, ElAlaoui RN, Cherkaoui M, Hemida MG.   +6 more
europepmc   +1 more source

Community-based integrated care for HIV, viral hepatitis and sexually transmitted infections, Thailand. [PDF]

Bull World Health Organ
Wansom T, Thongmee A, Chittmittrapap S, Saraporn T, Chavalertsakul K, Chotirosniramit N, Pattarakijroongrueng S, Palakawong Na Ayuthaya T, Verachai V, Traisirichok P, Intharabut B, Linn N, Teuansiri R, Kulprayong K, Waesateh A, Lawseng S, Chumwangwapee T, Pattarasuteewong S, Pudpong N, Unchit D, Photipap J, Wongsuwon C, Werapattanawong N, Smahoh S, Sae-Chee P, Phueakchai S, Kittikoonprasert P, Bootsan P, Lawpoolsri S, Creac'H P, Mills S, Yoocharoen P, Avihingsanon A, Phanuphak N, Riewpaiboon A, Durier N, C-Free Study Group..   +36 more
europepmc   +1 more source

Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study. [PDF]

BMJ Open
Jafari M, Mehdizadeh P, Keshavarz K, Teymourzadeh E, Abyazi MA, Gholamreza Shirazi P.   +5 more
europepmc   +1 more source